1. Acute Coronary Syndrome After Infliximab Infusion
- Author
-
Sharon C. Reimold, Andreas M. Reimold, Daniel Scheurich, and Moeen Abedin
- Subjects
musculoskeletal diseases ,Cardiac Catheterization ,Acute coronary syndrome ,medicine.medical_specialty ,Nausea ,medicine.medical_treatment ,Arthritis ,Coronary Disease ,Chest pain ,Arthritis, Rheumatoid ,Electrocardiography ,Internal medicine ,medicine ,Humans ,Myocardial infarction ,Infusions, Intravenous ,skin and connective tissue diseases ,Cardiac catheterization ,business.industry ,Antibodies, Monoclonal ,Syndrome ,General Medicine ,Middle Aged ,medicine.disease ,Infliximab ,Antirheumatic Agents ,Rheumatoid arthritis ,Acute Disease ,Cardiology ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,medicine.drug - Abstract
The TNFalpha inhibitor infliximab is widely used in the treatment of rheumatoid arthritis and Crohn disease. Mild infusion reactions consisting of low-grade fever, headache, nausea, and fatigue are common, but we describe for the first time the occurrence of an acute coronary syndrome during infliximab administration. This case alerts infusion centers to consider the possibility that chest pain and dyspnea during infliximab infusion can represent a myocardial infarction, even in younger patients without a history of cardiac disease.
- Published
- 2006
- Full Text
- View/download PDF